GlassScriptPhysician profile
Tatiana E Swanson
NPI 1275367252
$1,017.96
in general payments reported to CMS, 2019-2025
21 companies · $781 in 2025
The $781 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $237 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.01 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $143.69 | 2024-2025 | Trodelvy |
| Sobi, INC | $132.88 | 2025 | |
| Myriad Genetic Laboratories, INC. | $132.68 | 2024 | Myrisk |
| Pfizer INC. | $77.64 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $59.87 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.58 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.82 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.96 | 2025 | Eliquis, Opdivo |
| Merck Sharp & Dohme LLC | $42.31 | 2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $37.21 | 2025 | Erleada, Rybrevant |
| Eisai INC. | $31.91 | 2025 | |
| Sumitomo Pharma America, INC. | $29.39 | 2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $27.89 | 2025 | Ninlaro |
| Lilly USA, LLC | $26.69 | 2024 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $22.66 | 2024 | Enhertu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.71 | 2025 | Vyloy |
| Array Biopharma INC | $18.56 | 2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $17.31 | 2024 | Tevimbra |
| Tersera Therapeutics LLC | $17.05 | 2025 | Zoladex |
| Exelixis INC. | $16.70 | 2025 | Cabometyx |
| Geron Corporation | $15.45 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tatiana Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.